
The worrying number of deaths associated with Nuplazid has eyes returning to the pipeline for Parkinson’s disease. Anjali Shukla, a …

Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive …

Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an …

Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …

Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, …

The FlyPharma Conference Europe wrapped up for another year on 6 June, returning with an expanded roster of speakers who …

The decision to award the EMA headquarters to Amsterdam was a contentious one, not least because the vote had to …

Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …

Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

When rumours first started rumbling about a mega-merger between Bayer and Monsanto, one of the major question marks was on …

Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …

The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …

The headline figure is that the NHS budget deficit for the year 2017/2018 came in at £960 million, close to …

Allergan’s share price has been on a steady downward trajectory for the last year and investors are becoming increasingly frustrated …